Brief: Monopar Presents Data Showing Tumor Reduction Benefit Of Camsirubicin From Ongoing Phase 1b At The 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
01/11/2023 11:27
Nov 1 (Reuters) - Monopar Therapeutics Inc MNPR.O :
* MONOPAR PRESENTS DATA SHOWING TUMOR REDUCTION BENEFIT OF
CAMSIRUBICIN FROM ONGOING PHASE 1B AT THE 2023 CONNECTIVE TISSUE
ONCOLOGY SOCIETY (CTOS) ANNUAL MEETING
* MONOPAR THERAPEUTICS INC - NO DOSE-LIMITING TOXICITY, AS
DEFINED
IN PROTOCOL, HAS BEEN OBSERVED TO-DATE
Source text for Eikon: ID:nGNX73CDV
Further company coverage: MNPR.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on Monopar Therapeutics
See all newsBrief: Monopar Appoints Jeffrey D. Kent, M.D., As Executive Vice President, Head Of Medical Affairs Announces Two Alxn1840 Presentations At Aasld – The Liver Meeting 2026
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Monopar Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Monopar Therapeutics Inc. expected to post a loss of 62 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Alphabet, IBM, Tesla